Generation, secretion and degradation of cancer immunotherapy target PD-L1

Cancer immunotherapy is a rapidly developing and effective method for the treatment of a variety of malignancies in recent years. As a significant immune checkpoint, programmed cell death 1 ligand 1 (PD-L1) and its receptor programmed cell death protein 1 (PD-1) play the most significant role in can...

Full description

Saved in:
Bibliographic Details
Published in:Cellular and molecular life sciences : CMLS 2022-08, Vol.79 (8), p.413-413, Article 413
Main Authors: Shen, Dan-Dan, Bi, Ya-Ping, Pang, Jing-Ru, Zhao, Li-Juan, Zhao, Long-Fei, Gao, Ya, Wang, Bo, Liu, Hui-Min, Liu, Ying, Wang, Ning, Zheng, Yi-Chao, Liu, Hong-Min
Format: Article
Language:English
Subjects:
Antibodies
Apoptosis
B7-H1 Antigen - metabolism
Biochemistry
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer immunotherapy
Cell Biology
Cell death
Clinical trials
Degradation
Drug delivery
Drug development
Gene expression
Humans
Immune checkpoint
Immunosuppressive agents
Immunotherapy
Immunotherapy - methods
Life Sciences
mRNA
Neoplasms - metabolism
PD-1 protein
PD-L1 protein
Post-translation
Programmed Cell Death 1 Receptor - metabolism
Protein Processing, Post-Translational
Review
RNA modification
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer immunotherapy is a rapidly developing and effective method for the treatment of a variety of malignancies in recent years. As a significant immune checkpoint, programmed cell death 1 ligand 1 (PD-L1) and its receptor programmed cell death protein 1 (PD-1) play the most significant role in cancer immune escape and cancer immunotherapy. Though PD-L1 have become an important target for drug development and there have been various approved drugs and clinic trials targeting it, and various clinical response rate and adverse reactions prevent many patients from benefiting from it. In recent years, combination trials have become the main direction of PD-1/PD-L1 antibodies development. Here, we summarized PD-L1 biofunctions and key roles in various cancers along with the development of PD-L1 inhibitors. The regulators that are involved in controlling PD-L1 expression including post-translational modification, mRNA level regulation as well as degradation and exosome secretory pathway of PD-L1 were focused. This systematic summary may provide comprehensive understanding of different regulations on PD-L1 as well as a broad prospect for the search of the important regulator of PD-L1. The regulatory factors of PD-L1 can be potential targets for immunotherapy and increase strategies of immunotherapy in combination.
ISSN:1420-682X
1420-9071
DOI:10.1007/s00018-022-04431-x